Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by US Bancorp DE

US Bancorp DE cut its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 72.9% during the fourth quarter, Holdings Channel reports. The institutional investor owned 2,130 shares of the company’s stock after selling 5,736 shares during the period. US Bancorp DE’s holdings in Protagonist Therapeutics were worth $82,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of PTGX. Victory Capital Management Inc. raised its position in shares of Protagonist Therapeutics by 1,729.3% during the 3rd quarter. Victory Capital Management Inc. now owns 130,797 shares of the company’s stock worth $5,886,000 after acquiring an additional 123,647 shares in the last quarter. Mutual of America Capital Management LLC purchased a new position in Protagonist Therapeutics in the third quarter valued at approximately $399,000. Thrivent Financial for Lutherans acquired a new stake in Protagonist Therapeutics during the third quarter worth approximately $2,082,000. Quest Partners LLC lifted its position in shares of Protagonist Therapeutics by 885.1% during the 3rd quarter. Quest Partners LLC now owns 23,947 shares of the company’s stock worth $1,078,000 after buying an additional 21,516 shares during the last quarter. Finally, Segall Bryant & Hamill LLC boosted its holdings in shares of Protagonist Therapeutics by 1.5% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 120,301 shares of the company’s stock valued at $5,414,000 after buying an additional 1,739 shares in the last quarter. 98.63% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CEO Dinesh V. Ph D. Patel sold 5,359 shares of the stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $38.18, for a total value of $204,606.62. Following the transaction, the chief executive officer now directly owns 540,260 shares of the company’s stock, valued at approximately $20,627,126.80. This trade represents a 0.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Arturo Md Molina sold 30,514 shares of the firm’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $55.74, for a total value of $1,700,850.36. Following the completion of the transaction, the insider now owns 83,892 shares in the company, valued at approximately $4,676,140.08. This trade represents a 26.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 60,776 shares of company stock worth $3,368,010. 5.40% of the stock is owned by insiders.

Protagonist Therapeutics Stock Performance

PTGX opened at $53.01 on Tuesday. Protagonist Therapeutics, Inc. has a one year low of $24.22 and a one year high of $60.60. The company has a market cap of $3.25 billion, a price-to-earnings ratio of 19.93 and a beta of 2.34. The business’s fifty day moving average is $39.93 and its two-hundred day moving average is $42.31.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings data on Friday, February 21st. The company reported $1.98 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $2.07. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. The firm had revenue of $170.64 million during the quarter, compared to the consensus estimate of $56.65 million. On average, analysts predict that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on PTGX shares. The Goldman Sachs Group dropped their price objective on Protagonist Therapeutics from $43.00 to $38.00 and set a “neutral” rating on the stock in a report on Monday, February 24th. JMP Securities reiterated a “market outperform” rating and issued a $58.00 price objective on shares of Protagonist Therapeutics in a research note on Friday, February 7th. StockNews.com lowered shares of Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 10th. BTIG Research set a $73.00 price target on shares of Protagonist Therapeutics in a research report on Monday, March 3rd. Finally, JPMorgan Chase & Co. raised their price objective on shares of Protagonist Therapeutics from $53.00 to $57.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $61.22.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.